Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli

Brain Research

Volumn 815, Issue 2, 1999, Pages 237-242

  McShea, Andrew ^b   Zelasko, Dawn A ^a   Gerst, Jennifer L ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Alzheimer's disease; Cell cycle; Grb2; Signal transduction; SOS 1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CELL CYCLE; FRONTAL LOBE; GRB2 ADAPTOR PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEURONS; PHOSPHORYLATION; PROTEINS; RAS GUANINE NUCLEOTIDE EXCHANGE FACTORS; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 0033537306     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01135-4     Document Type: Article

References (46)

1. Aktas H., Cai H., Cooper G.M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the CDK inhibitor p27KIP1. Mol. Cell. Biol. 17:1997;3850-3857.
2. Arendt T., Holzer M., Grossman A., Zedlick D., Bruckner M.K. Increased expression and subcellular translocation of the mitogen-activated protein kinase and the mitogen-activated protein kinase in Alzheimer's disease. Neuroscience. 68:1995;5-18.
3. Arendt T., Rodel L., Gartner U., Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. NeuroReport. 7:1996;3047-3049.
4. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336:1993;417-424.
5. Bittman K., Owens D.F., Kriegstein A.R., LoTurco J.J. Cell coupling and uncoupling in the ventricular zone of developing neocortex. J. Neurosci. 17:1997;7037-7044.
6. Chardin P., Camonis J.H., Gale N.W., van Aelst L., Schlessinger J., Wigler M.H., Bar-Sagi D. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 260:1993;1338-1343.
7. Crutcher K.A., Scott S.A., Liang S., Everson W.V., Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J. Neurosci. 13:1993;2540-2550.
8. Fan J., Bertino J.R. K-ras modulates the cell cycle via positive and negative regulatory pathways. Oncogene. 14:1997;2595-2607.
9. Filmus J., Robles A.I., Shi W., Wong M.J., Colombo L.L., Conti C.J. Induction of cyclin D1 expression by activated ras. Oncogene. 9:1994;3627-3633.
10. Gartner U., Holzer M., Heumann R., Arendt T. Induction of p21ras in Alzheimer pathology. NeuroReport. 6:1995;1441-1444.
11. Gómez-Pinilla F., Cummings B.J., Cotman C.W. Induction of basic fibroblast growth factor in Alzheimer's disease pathology. NeuroReport. 1:1990;211-214.
12. Huang R.P., Wu X.J., Fan Y., Adamson E.D. UV activates growth factor receptors via reactive oxygen intermediates. J. Cell. Biol. 133:1996;211-220.
13. Kawai M., Kalaria R.N., Harik S.I., Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am. J. Pathol. 137:1990;1435-1446.
14. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
15. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272:1997;17810-17814.
16. Ledesma M.D., Correas I., Avila J., Diaz-Nido J. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett. 308:1992;218-224.
17. Li J., Xu M., Zhou H., Ma J., Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell. 90:1997;917-927.
18. Liu W.K., Williams R.T., Hall F.L., Dickson D.W., Yen S.H. Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am. J. Pathol. 146:1995;228-238.
19. Masliah E., Mallory M., Alford M., Hansen L.A., Saitoh T. Immunoreactivity of the nuclear antigen p105 is associated with plaques and tangles in Alzheimer's disease. Lab. Invest. 69:1993;562-569.
20. McGeer P.L., Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 42:1992;447-449.
21. McShea A., Harris P.L.R., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators p16 and cdk4 in Alzheimer's disease. Am. J. Pathol. 150:1997;1933-1939.
22. A. McShea, A.F. Wahl, M.A. Smith, Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease, Med. Hypotheses, in press.
23. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van B.G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
24. Nagy Z., Esiri M.M., Smith A.D. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol. 93:1997;294-300.
25. Nagy Z., Esiri M.M., Cato A.M., Smith A.D. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol. 94:1997;6-15.
26. Olson L. NGF and the treatment of Alzheimer's disease. Exp. Neurol. 124:1993;5-15.
27. Yan C.Y.J., Greene L.A. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J. Neurosci. 18:1998;4042-4049.
28. Rao G.N. Hydrogen peroxide induces complex formation of SHC-GRB-2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-related protein kinases group of mitogen-activated protein kinases. Oncogene. 13:1996;713-719.
29. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
30. Shirvan A., Ziv I., Machlin T., Zilkha-Falb R., Melamed E., Barzilai A. Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. J. Neurochem. 69:1997;539-549.
31. Simon M.A., Bowtell D.D., Dodson G.S., Laverty T.R., Rubin G.M. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell. 67:1991;701-716.
32. Smith T.W., Lippa C.F. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 54:1995;297-303.
33. Smith M.A., Kutty R.K., Richey P.L., Yan S.-D., Stern D., Chader G.J., Wiggert B., Petersen R.B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
34. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.-D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA. 91:1994;5710-5714.
35. Smith M.A., Siedlak S.L., Richey P.L., Nagaraj R.H., Elhammer A., Perry G. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res. 717:1996;99-108.
36. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
37. Smith M.A., Harris P.L.R., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653-2657.
38. M.A. Smith, G. Perry, L.M. Sayre, Protein oxidation and glycation in neurodegenerative diseases, in: L. Montagnier, R. Olivier, C. Pasquier (Eds.), Oxidative Stress in Cancer, AIDS, and Neurodegenerative Diseases, Marcel Dekker, New York, 1998, pp. 485-496.
39. Stein L.S., Boonstra J., Burghardt R.C. Reduced cell-cell communication between mitotic and nonmitotic coupled cells. Exp. Cell. Res. 198:1992;1-7.
40. L.A. Sternberger, Immunocytochemistry, 3rd edn., Wiley, New York, 1986.
41. Stoppa E.G., Gonzalez A.-M., Chorsky R., Corona R.J., Alvarez J., Bird E.D., Baird A. Basic fibroblast growth factor in Alzheimer's disease. Biochem. Biophys. Res. Commun. 171:1990;690-696.
42. van der Wal E., Gómez F., Cotman C.W. Transforming growth factor-β1 is in plaques in Alzheimer's and Down's pathologies. NeuroReport. 4:1993;69-72.
43. Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease? J. Cell. Biol. 132:1996;413-425.
44. Wolozin B.L., Pruchnicki A., Dickson D.W., Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 232:1986;648-650.
45. Park D.S., Levine B., Ferrari G., Greene L.A. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17:1997;8975-8983.
46. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.